Fully Synthetic Vaccines Consisting of Tumor‐Associated MUC1 Glycopeptides and a Lipopeptide Ligand of the Toll‐like Receptor 2

Fragment condensation of a protected Pam3Cys lipopeptide with unprotected tumor-associated MUC1 glycopeptides opens the way to vaccine candidates such as A. These vaccines elicit selective immune responses in mice although they lack an immunodominant carrier protein. In principle, such vaccines are applicable to humans.